Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
By T. Imperiale, D. Ransohoff, S. Itzkowitz, B. Turnbull, M. Ross. New England Journal of Medicine, 2004
834 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/62e7d01a5cd699e0da5493c0cd05e93ecb11980d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pathology and Forensic Medicine
Citations in the corpus
- ACG Clinical Guidelines: Colorectal Cancer Screening 2021. (2021, methodology): “The multitarget stool DNA (mtsDNA) test is an FDA-approved stool test that comprises an assay for mutant KRAS, methylated BMP3, methylated NDRG4, and a FIT for hemoglobin (39).”